Literature DB >> 22303982

Mitotic rate and subcutaneous involvement are prognostic factors for survival after recurrence in patients with only locoregional skin metastasis as the first site of recurrence from cutaneous melanoma.

F Messeguer1, A Agustí-Mejías, V Traves, C Requena, V Alegre, C Guillén, V Oliver, E Nagore.   

Abstract

BACKGROUND: Few reports on literature give detailed figures on prognostic factors of locoregional skin recurrence in cutaneous melanoma.
OBJECTIVE: The aim of this study was to evaluate clinical and histological prognostic factors following development of locoregional cutaneous metastasis as the only progression site from melanoma.
METHODS: Data from 1327 stage I and II melanoma patients who visited Instituto Valenciano de Oncología and Consorcio Hospital General Universitario de Valencia from 2000 to 2010 were documented in a prospective manner. During follow up, 112 (8.4%) of them developed recurrent disease. A retrospective analysis revealed a subset of 36 patients with locoregional cutaneous metastases as a first event.
RESULTS: Significant prognostic factors in the univariate analysis were Breslow thickness, tumor mitotic rate and the presence subcutaneous involvement of the skin metastasis. After multivariate analysis the independent predictive factors for survival after recurrence were tumor mitotic rate (hazard ratio [HR]: 8.6; 95% CI: 1.0-77.2) and subcutaneous involvement of the skin metastasis (HR: 4.3; 95% CI: 1.0-18.5).
CONCLUSION: The survival after recurrence of melanoma patients that has relapsed with only locoregional cutaneous metastasis depends on the mitotic rate of the primary tumor and the subcutaneous involvement of the metastasis.
© 2012 The Authors. Journal of the European Academy of Dermatology and Venereology © 2012 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2012        PMID: 22303982     DOI: 10.1111/j.1468-3083.2012.04454.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  4 in total

1.  Inhibition of SATB1 by shRNA suppresses the proliferation of cutaneous malignant melanoma.

Authors:  Lei Zhang; Fang Cheng; Runzhi He; Hao Chen; Yi Liu; Jianfang Sun
Journal:  Cancer Biother Radiopharm       Date:  2014-01-07       Impact factor: 3.099

2.  Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumour.

Authors:  Benjamin Weide; Christine Faller; Margrit Elsässer; Petra Büttner; Annette Pflugfelder; Ulrike Leiter; Thomas Kurt Eigentler; Jürgen Bauer; Friedegund Meier; Claus Garbe
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

3.  High nevus counts confer a favorable prognosis in melanoma patients.

Authors:  Simone Ribero; John R Davies; Celia Requena; Cristina Carrera; Daniel Glass; Ramon Rull; Sergi Vidal-Sicart; Antonio Vilalta; Lucia Alos; Virtudes Soriano; Pietro Quaglino; Victor Traves; Julia A Newton-Bishop; Eduardo Nagore; Josep Malvehy; Susana Puig; Veronique Bataille
Journal:  Int J Cancer       Date:  2015-04-11       Impact factor: 7.396

4.  Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis.

Authors:  Benjamin Weide; Christine Faller; Petra Büttner; Annette Pflugfelder; Ulrike Leiter; Thomas Kurt Eigentler; Jürgen Bauer; Andrea Forschner; Friedegund Meier; Claus Garbe
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.